日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancer

一项随机临床疗效和安全性研究,比较了peltopepimut-S联合cemiplimab与单用cemiplimab治疗复发/转移性HPV16阳性头颈癌患者的疗效和安全性。

Even, Caroline; Harrington, Kevin J; Massarelli, Erminia; Laban, Simon; Fayette, Jérôme; Oliva, Marc; Klein Hesselink, Marielle; Visscher, Sonja; Fury, Matthew G; Wiekmeijer, Anna-Sophia; Licitra, Lisa; Melichar, Bohuslav; Devriese, Lot A; Braña, Irene; Jankowska, Petra; Posner, Marshall; Glisson, Bonnie; Kong, Anthony; Hooftman, Leon; Melief, Cornelis J M MD,; Ferrarotto, Renata